Tianjin Med J ›› 2015, Vol. 43 ›› Issue (3): 333-336.doi: 10.11958/j.issn.0253-9896.2015.03.030
• Review • Previous Articles
LI Junying， LI Hong
Received:
Revised:
Published:
Online:
Contact:
LI Junying， LI Hong. Advances of vascular endothelial growth factor inhibitors in the treatment of psoriasis[J]. Tianjin Med J, 2015, 43(3): 333-336.
Abstract: Psoriasis is a common inflammatory autoimmune disease. Angiogenesis is known to be a key pathogenic fea⁃ ture of psoriasis. The elevation of vascular endothelial growth factor (VEGF) has been demonstrated in the skin and plasma of patients with psoriasis. A number of case reports have indicated that VEGF inhibitor is effective in patients with psoriasis. VEGF inhibitors are consisted of three categories: anti-VEGF monoclonal antibodies, VEGF receptor antagonists and tyro⁃ sine kinase inhibitors. This article reviewed the current clinical application and therapeutic potential of VEGF inhibitors in psoriasis .
Key words: psoriasis, vascular endothelial growth factors, VEGF inhibitor
/ Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.tjyybjb.ac.cn/EN/10.11958/j.issn.0253-9896.2015.03.030
https://www.tjyybjb.ac.cn/EN/Y2015/V43/I3/333
